Invex Therapeutics (ASX:IXC) Volatility: 78.28% (As of Jun. 25, 2026)


ASX:IXC Invex Therapeutics Ltd ASX:IXC
37 GF Score
Price A$0.11
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics Volatility?

Invex Therapeutics ASX:IXC 37 Volatility is 78.28% as of Jun. 25, 2026. GuruFocus rates ASX:IXC with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-25), Invex Therapeutics's Volatility is 78.28%.

Invex Therapeutics  (ASX:IXC) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Invex Therapeutics Volatility Related Terms

ASX:IXC vs VRTX, REGN, ALNY: Volatility Comparison

For the Biotechnology subindustry, Invex Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Volatility falls into.


ASX:IXC
37GF Score
Invex Therapeutics Ltd ASX:IXC
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics  (ASX:IXC) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 78.28% mean?
Invex Therapeutics (ASX:IXC) has a Volatility of 78.28% as of Jun. 25, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Volatility too high?
Invex Therapeutics' current Volatility is 78.28%. Overall, Invex Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Volatility compare to VRTX and REGN?
Invex Therapeutics' Volatility of 78.28% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Volatility is 78.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Volatility of 78.28%. The current Volatility is 78.28%. Invex Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Volatility is 78.28% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
37GF Score

Get the complete analysis for ASX:IXC

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price